Benzinga · Jul 13, 2026
Launch One Acquisition's Shareholders Approve Extension Of Business Combination Deadline To January 15, 2027
https://www.sec.gov/ix?doc=/Archives/edgar/data/0002015502/000121390026077654/ea0297864-8k_launch.htm
LP
NASDAQ · LPAA
Launch One Acquisition Corp.
Financial Services · Shell Companies
$10.85
Up+$0.03 (+0.28%)
Updated Oct 11, 2026, 7:55 AM
SID Score
4.5/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 303.6M
- P/E ratio
- 27.52
- Dividend yield
- 0.00%
- 52-week range
- $10.39 – $11.67
- Volume
- 6.82K
- Avg. volume
- 14.98K
Price performance · LPAA
LPAA price history
1M range · 2 trading sessions · Daily adjusted prices
Prices through Oct 1, 2026
LPAA closed at $10.85 after 2 trading sessions, up 0.18% for the selected period.
- Last close
- $10.85
- Period change
- +0.18%
- Period low
- $10.83
- Period high
- $10.85
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 1, 2026 | $10.85 | $10.85 | $10.85 | $10.85 | 6.82K |
| Sep 30, 2026 | $10.81 | $10.83 | $10.81 | $10.83 | 4.07K |
Latest LPAA news
The latest Smart Investors Daily articles mentioning LPAA.
Stock researchCompany · Overview
Company
Market Activity
Research & News
LPAA research
Overview
Company profile and research snapshot.
Company profile
Launch One Acquisition Corp is a blank check company.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Benzinga · Oct 15, 2025
Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics received FDA Orphan Drug Designation for MNV-201, a novel cell therapy targeting Myelodysplastic Syndrome (MDS), and announced a planned business combination with Launch One Acquisition Corp.
Benzinga · Sep 18, 2025
Minovia Therapeutics Receives FDA Fast Track Designation for MNV-201 in Myelodysplastic Syndrome
Minovia Therapeutics received FDA Fast Track Designation for MNV-201, its investigational compound targeting Myelodysplastic Syndrome (MDS), potentially accelerating drug development and review process.
Benzinga · Jun 25, 2025
Minovia Therapeutics Ltd. and Launch One Acquisition Corp. Announce Proposed Business Combination to Create Nasdaq-Listed Mitochondrial Therapy Company in $1 Trillion+ Mitochondrial and Longevity Markets
Minovia Therapeutics, a clinical-stage biotechnology company, and Launch One Acquisition Corp., a SPAC, have announced a proposed business combination to create a Nasdaq-listed mitochondrial therapy company focused on rare diseases and longevity.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
